Tech Company Financing Transactions
Syneron Bio Funding Round
On 4/3/2026, Syneron Bio raised $150 million in Series B financing from CDH Investments, Decheng Capital and 5Y Capital.
Transaction Overview
Company Name
Announced On
4/3/2026
Transaction Type
Venture Equity
Amount
$150,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to further advance the intelligent evolution of its proprietary macrocyclic peptide discovery platform, Synova�, and to accelerate the progression of its diversified innovative pipeline into clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Beijing, Undisclosed
China
Beijing, Undisclosed
China
Phone
Undisclosed
Email Address
Not Recorded
Overview
Syneron Bio is a biotech company dedicated to the development of next-generation macrocyclic peptide therapeutics, employing its proprietary Synova� platform. The company has built a robust pipeline targeting oncology and chronic diseases. With a team experienced in drug development and data science.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Xiao Zhang
Browse more venture capital transactions:
Prev: 4/2/2026: Anvil Robotics venture capital transaction
Next: 4/3/2026: Alien venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs